European Parliament supports rigorous measures to monitor adverse effects of medicines

The European Parliament’s Committee for Environment, Public Health and Food Safety has unanimously approved two reports by Linda McAvan (S&D, UK) on amendments to the EU pharmacovigilance legislation.  In her reports Ms. McAvan fully agrees with the measures proposed by the European Commission.

An update of EU pharmacovigilance rules means to protect the citizens from recurrence of cases like the case of the French "Médiator" diabetes medicine which led to many deaths.

According to this new proposal, any report of adverse effects of a medicinal product would trigger an automatic EU safety evaluation by the Pharmacovigilance Risk Assessment Committee. New drugs containing new active substances will also be labelled with a black triangle symbol, so that patients and healthcare professionals could easily identify them.

MEP Linda McEvan is now working on the first reading agreement with Council. The plenary vote is scheduled to take place at the beginning of July 2012.

More information is available here:
Towards better detection and EU-wide withdrawal of dangerous medicines

 
EU Health Workforce Action Plan revealed

The EU healthcare sector represents a huge employment potential as a result of the rapidly ageing population and growing demand in medical care. However, a number of obstacles slow down the growth in this sector and can potentially endanger the quality of care:

  • Lack of young recruits to replace the retiring healthcare personnel
  • Care for the elderly requires new skills and treatments and a better knowledge of chronic conditions
  • Some health professions are not attractive for the youth due to hard working conditions, stressful environment, poor work-life balance, relatively low salaries compared to some other sectors
  • Severe shortages of health workforce in rural areas and oversupply in some urban areas

To address these challenges the European Commission published on April 18, 2012 an Action Plan for the EU Health Workforce. The Action Plan proposes a set of actions to be carried out in 3 domains:

  1. Forecasting workforce needs and improving workforce planning methodologies
  2. Anticipating future skills needs 
  3. Sharing good practice on effective recruitment and retention strategies for health professionals

Once adopted, the Action Plan will be implemented by the Commission in cooperation with all Member States. The text has been submitted to the Employment and Social Affairs Committee of the European Parliament for consideration. Its full text is available:

COMMISSION STAFF WORKING DOCUMENT on an Action Plan for the EU Health Workforce

 
UEMO to give its opinion on the cross-border recognition of prescriptions

The UEMO has submitted its response to the EU public consultation on the recognition of prescriptions issued in another Member State.  The consultation procedure was launched in October 2011 and continued until beginning of January 2012. A number of patient and doctors associations as well as manufacturers of medicinal products and medical devices were invited to submit their comments on the following issues:

•    how to verify the authenticity of a prescription issued in another Member State
•    how to solve the problem of substitution of a medicinal product prescribed in one Member State and dispensed in another
•    how to make prescriptions and product instructions more comprehensible for patients

Read more...
 
Denmark's priorities of EU health policy.docx Denmark's priorities of EU health policy

After having started its EU Council presidency on January 1st 2012, Denmark has presented its health policy priorities. The country’s strategy is to build on the achievements of its predecessors to ensure consistency of the EU health policy.

The Danish Presidency is posed to keep on working on the Antimicrobial Resistance (AMR) as the rising level of resistance due to the increased use of antibiotics remains a challenge for most European countries. Denmark’s focus will be on reducing the use of antibiotics in humans and animals.

Read more...